SelectQuote Faces Mixed Results Amid Changing Medicare Advantage Landscape

SelectQuote Faces Mixed Results Amid Changing Medicare Advantage Landscape SelectQuote, Inc. (NYSE: SLQT) noted a significant 18% decrease in Medicare Advantage policy approvals during the first fiscal quarter of 2027 compared to the previous year. This decline contributed to a drop in total revenue, from $329 million to $280 million. Interestingly, while volume dipped, the lifetime value (LTV) of commissions per approved policy increased by 16%, reaching $890 from $769. This dichotomy signals shifts within the broader Medicare distribution arena as the Annual Enrollment Period nears its December 7, 2026, end date. As SelectQuote navigates this complex market environment, an analysis by Oliver Wyman of CMS data reveals that approximately 2.8 million Medicare Advantage members are affected by plan terminations for 2027. This 13% of 2026's enrollments now requires new coverage due to the exit of eleven insurers from the individual Medicare Advantage market. Consequently, insurers are adjusting their distribution expenditures, impacting commission structures industry-wide.

Commission Adjustments During Market Shifts

A notable element is the variability in commission offerings among insurers like Aetna, which has decided not to offer commissions on 123 plans across 33 states for the 2027 plan year. Such fluctuations allow certain policy commissions to rise while others stagnate. Amidst these changes, SelectQuote reported an improved revenue-to-customer-acquisition-cost ratio from 6.4x to 7x. This efficiency, highlighted in their recent earnings call, underscores the company’s strategic adjustments in response to market conditions.

Streamlining Operations for Enhanced Efficiency

SelectQuote has taken decisive steps to optimize operations by reducing its senior agent workforce for the Annual Enrollment Period. This move aims to leverage a more capable, albeit smaller, team, matching knowledgeable Medicare beneficiaries with appropriate plans. CEO Tim Danker emphasized that these experienced agents meet the evolving needs of their demographic effectively, resulting in an adjusted EBITDA loss reduction in the senior segment from $21 million to $12.3 million year-over-year. The company's Healthcare Services segment, particularly SelectRx, faced headwinds with a 16% revenue decline, attributed to reimbursement issues and stricter membership criteria. However, the segment's adjusted EBITDA rose by 56%, suggesting increased profitability despite the membership drop.
Segment Revenue Adjusted EBITDA Growth
Senior $280 million Lowered loss from $21M to $12.3M
SelectRx $186 million Increased by 56%
Life Insurance $42.8 million Improved margin from 12% to 17%

Litigation and Projections

In a separate development, SelectQuote is defending against a federal False Claims Act litigation in Massachusetts. The allegations claim illegal kickbacks between 2016 and 2021 for directing Medicare Advantage customers towards specific insurers. SelectQuote categorically denies these accusations, with current discovery proceedings as of a September 2026 court order. Despite market hurdles and legal battles, SelectQuote remains optimistic, projecting revenues between $1.35 billion and $1.45 billion for fiscal 2027, with an adjusted EBITDA forecast between $90 million and $115 million. Operating cash flow is expected to exceed $60 million, showcasing the company's resiliency in a rapidly evolving market. This evolution, shaped by both rising commission values and strategic non-commissions, reflects SelectQuote’s adaptability to ongoing industry changes.